CLUSTERS OF IMMUNE CHECKPOINTS IN MULTIPLE MYELOMA UNVEILS PATIENTS’ STRATIFICATION AND SINERGISTIC IMMUNOTHERAPY
EHA Library, Laura Martinez-Verbo, 421473
THE ROLE OF PROLIFERATING STEM-LIKE PLASMA CELLS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: INSIGHTS FROM SINGLE-CELL RNA SEQUENCING AND PROTEOMIC ANALYSIS
EHA Library, Jiadai Xu, 421474
INCIDENCE AND INCIDENCE TRENDS OF MULTIPLE MYELOMA AND PLASMA CELL NEOPLASMS IN NORTHEAST SPAIN, 1994-2020
EHA Library, rafael marcos-gragera, 421475
UNLOCKING MULTIPLE MYELOMA INSIGHTS: ESTABLISHMENT OF A XENOGRAFT MODEL ON THE CHICK EMBRYO CHORIOALLANTOIC MEMBRANE FOR TUMOUR GROWTH AND DRUG TESTING STUDIES
EHA Library, Izabela Cymer, 421476
IMPACT OF OPIOID USE ON LONG-TERM SURVIVAL IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
EHA Library, Marta Hidalgo, 421477
THE ROLE OF GALECTIN-3 IN MULTIPLE MYELOMA WITH KIDNEY DAMAGE
EHA Library, Zhanna Kozich, 421478
TRIPLE AND PENTA-REFRACTORY MULTIPLE MYELOMA IN IRELAND; A NATIONAL STUDY OF TREATMENT REGIMEN UTILIZATION AND RESISTANCE PATTERNS.
EHA Library, Jimmy William, 421480
ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS
EHA Library, Viktoria Khyshova, 421481
OUTCOME OF OCTOGENARIAN PATIENTS WITH MULTIPLE MYELOMA TREATED OUTSIDE CLINICAL STUDIES, FOCUSING ON TOLERABILITY AND EFFICACY OF TREATMENT
EHA Library, Dana Amsterdam, 421482
RESULTS FROM THE CHINA COHORT OF THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB (TEC) TREATMENT IN PATIENTS (PTS) WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Zhen Cai, 421483
SELINEXOR COMBINED BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
EHA Library, Yuping Zhong, 421484
MAINTENANCE THERAPY WITH IXAZOMIB VERSUS LENALIDOMIDE IN NEWLY-DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
EHA Library, Xuzhao Zhang, 421485
DELETION OF 1P32 IS AN ADVERSE PROGNOSTIC FACTOR FOR MULTIPLE MYELOMA PATIENTS :A SINGLE-CENTER STUDY IN CHINA
EHA Library, Juan Li, 421486
OUTCOME OF MULTIPLE MYELOMA WITH ASSOCIATED BONE INDEPENDENT EXTRAMEDULLARY DISEASE (EMD) - A UK SINGLE CENTER EXPERIENCE
EHA Library, Ke Xu, 421487
VASCULAR ENDOTHELIAL GROWTH FACTOR IS NOT THE BEST ASSESSMENT OF EFFICACY IN POEMS SYNDROME
EHA Library, Juan Li, 421488
PRIMARY RESULTS OF A PHASE 1/2 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Shinsuke Iida, 421489
IMMAGINE-3: A PHASE 3, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ANITOCABTAGENE AUTOLEUCEL (ANITO-CEL) WITH STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Library, Thomas Martin, 421490
LOW-DOSE APIXABAN AS PRIMARY THROMBOPROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA ON IMMUNOMODULATORY DRUGS
EHA Library, Carlos Aguilar, 421492
TREATMENT OF NEWLY DIAGNOSED FRAIL MULTIPLE MYELOMA PATIENTS WITH LENALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE
EHA Library, Maher Salamoon, 421493
HIGH BONE MARROW PLASMA CELL PERCENTAGE MAY IMPROVE THE R-ISS RISK STRATIFICATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE-CENTRE REAL-WORLD EXPERIENCE IN CHINA
EHA Library, Ning Liu, 421494
REAL-WORLD EFFECTIVENESS AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN CHINESE PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA: A SINGLE-ARM PROSPECTIVE STUDY
EHA Library, Weili Zhao, 421495
SPINAL -CORD COMPRESSION IN MULTIPLE MYELOMA . ALGERIAN MULTICENTER RETROSPECTIVE STUDY
EHA Library, Meriem benhalilou, 421496
EFFICACY AND SAFETY OF DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MOROCCAN SINGLE-CENTER REAL-LIFE STUDY.
EHA Library, Yasmine MOUTMIR, 421497
DYNAMIC INCREASE IN SERUM CHOLESTEROL LEVELS CONTRIBUTES TO LONG-TERM REMISSION AFTER AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
EHA Library, Yuan Chen, 421498
REAL-WORLD STUDY OF CARFILZOMIB-BASED CHEMOTHERAPY REGIMEN FOR THE TREATMENT OF MULTIPLE MYELOMA
EHA Library, Li Hui, 421499
CLINICAL STUDY OF ORAL REGIMEN FOR ELDERLY REFRACTORY MULTIPLE MYELOMA
EHA Library, Yuping Zhong, 421500
GLOMERULAR PROTEINURIA IN PATIENTS WITH TRIPLE CLASS REFRACTORY MULTIPLE MYELOMA DURING BELANTAMAB MAFODOTIN TREATMENT: A SINGLE CENTER EXPERIENCE
EHA Library, Laura Pavan, 421502
A SINGLE-CENTER STUDY ON THE USE OF THALIDOMIDE MAINTENANCE THERAPY FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Library, Lun-Wei Chiou, 421503
THE DIAGNOSTIC ENIGMA OF POEMS SYNDROME CASE SERIES FROM A SINGLE CENTRE
EHA Library, Bhavani Mandava, 421504
EXPRESSION AND PREDICTIVE VALUE OF CD24 ANTIGEN IN MULTIPLE MYELOMA PATIENTS
EHA Library, Mengru Liu, 421505
COMBINATION OF DARATUMUMAB AND BENDAMUSTINE IS AN EFFECTIVE TREATMENT FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
EHA Library, Hong Cen, 421506
LIMITED EFFICACY OF DARATUMUMAB IN HIGH RISK RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE REAL-LIFE EXPERIENCE
EHA Library, Sonia Morè, 421507
AN ANALYSIS OF CLONAL ISOTYPE SWITCHING (CIS) FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS: A RETROS STUDY
EHA Library, LIJING SHEN, 421508
CLINICAL STUDY ON PROPHYLACTIC USE OF TPO-RA TO PROMOTE MEGAKARYOCYTE RECONSTRUCTION IN PATIENTS WITH MM AFTER ASCT
EHA Library, Juan Li, 421509
REAL WORLD UTILISATION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA ACROSS EUROPE: A FEASIBILITY ASSESSMENT FOR THE MERMAID STUDY
EHA Library, Bruno Paiva, 421510
REAL-WORLD EVIDENCE EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
EHA Library, Benjamin A Derman, 421511
EFFICACY OF MELFLUFEN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND MUTATED OR DELETED TP53
EHA Library, Klara ACS, 421512
RETROSPECTIVE OBSERVATIONAL STUDY OF THE TREATMENT OF WALDENSTRÖM'S MACROGLOBULINEMIA WITH IBRUTINIB IN ROUTINE CLINICAL PRACTICE IN SPAIN
EHA Library, Eva Rubio Azpeitia, 421513
EARLY UNITED STATES (US) USERS OF TALQUETAMAB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A REAL-WORLD ANALYSIS OF PATIENT CHARACTERISTICS AND TREATMENT HISTORY
EHA Library, Hoa Le, 421515
CPD-DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM THE CTRIAL-IE 19-17 STUDY SHOWS EARLY EVIDENCE OF EFFICACY
EHA Library, Janusz Krawczyk, 421516
ENHANCING BENEFIT-RISK ASSESSMENT IN MULTIPLE MYELOMA USING MULTI-STATE MODELING IN THE RANDOMIZED PHASE 3 EMN02/HO95 TRIAL.
EHA Library, Anna Smit, 421517
TRIAL IN PROGRESS: ALUMMINATE RRMM – A RANDOMIZED PHASE 3 STUDY OF ALNUCTAMAB, A BCMA-TARGETING T-CELL ENGAGER, VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
EHA Library, Noffar Bar, 421518
PLASMA CELL LEUKEMIA, REAL WORLD EXPERIENCE IN A MULTICENTER MEXICAN COHORT
EHA Library, Paulina Ramirez, 421520
POMA-BASED THERAPY AFTER DARATUMUMAB: A SINGLE CENTER EXPERIENCE
EHA Library, Martina Lorenzon, 421521
EFFICACY AND SAFETY OF CARFILZOMIB PLUS POMALIDOMIDE AND DEXAMETHASONE AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN CHINA
EHA Library, Wenbin Qian, 421522
EFFICACY AND SAFETY OF THE CARFILZOMIB COMBINATION REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA IN CHINA: A REAL-WORLD ANALYSIS
EHA Library, Zhong-jun Xia, 421523
EFFICACY AND SAFETY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE FOR THE TREATMENT OF POEMS SYNDROME
EHA Library, Hao Li, 421524
PROGNOSTIC VALUE OF HEMOGLOBINE TO RED CELL DISTRIBUTION WIDTH RATIO FOR PATIENTS WITH MULTIPLE MYELOMA
EHA Library, Nikol Marošević, 421525
CHANGE OF ESTIMATED GLOMERULAR FILTRATION RATE ASSOCIATES WITH ALL-CAUSE MORTALITY IN MULTIPLE MYELOMA
EHA Library, Xiang Liu, 421527
DARATUMUMAB IS ONE OF THE MAIN DRIVERS OF OUTCOME IMPROVEMENT IN PATIENTS WITH AL AMYLOIDOSIS
EHA Library, Elena Alejo, 421528
DARATUMUMAB AND BORTEZOMIB AS MAINTENANCE IN NEWLY DIAGNOSED MYELOMA MULTIPLE IN NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION REAL LIFE PATIENTS.
EHA Library, María del Carmen Gilabert Gutiérrez, 421529
MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE: INSIGHTS FROM A TERTIARY REFERRAL CENTER EXPERIENCE IN MEXICO
EHA Library, Sergio Rodriguez-Rodriguez, 421530
SECONDARY HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH ANTI-CD38. EVALUATION OF CASES IN A HOSPITAL IN MADRID.
EHA Library, Gonzalo Benzo Callejo, 421531
REAL WORLD DATA OF RESPONSE TO DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) INDUCTION AND USE OF VTD AS BRIDGING CHEMOTHERAPY PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
EHA Library, Sneha Fernandes, 421532
REAL-WORLD EXPERIENCE OF QUADRUPLET INDUCTION TREATMENT, DARA-VTD FOR UNTREATED TRANSPLANT ELIGIBLE MYELOMA PATIENTS IN A UK NHS CANCER CENTRE
EHA Library, Salam Youssef, 421533
THE POSSIBILITIES OF USING HIGH-THROUGHPUT SEQUENCING IN PATIENTS WITH MULTIPLE MYELOMA
EHA Library, Daria Chebykina, 421534
COST AND HEALTHCARE UTILIZATION IN PATIENTS DIAGNOSED WITH MONOCLONAL GAMMOPATHY DURING THE EVALUATION OF ANEMIA
EHA Library, Mackenzie Maberry, 421535
SAFETY AND EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY MULTIPLE MYELOMA PATIENTS
EHA Library, arda bayar, 421536
6 CYCLES OF ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (I-VRD) VS. 3 CYCLES OF I-VRD PLUS HIGH-DOSE MELPHALAN IN IN NEWLY DIAGNOSED LOW-RISK MULTIPLE MYELOMA. THE ELIAS-TRIAL.
EHA Library, Theo Leitner, 421537
C-MYC IS A PREDICTIVE FACTOR OF OUTCOMES IN TRANSPLANT ELIGIBLE ELDERLY MULTIPLE MYELOMA PATIENTS
EHA Library, Fatma Keklik Karadag, 421538
THE CLINICAL CHARACTERISTICS AND PROGNOSTIC MODELS OF PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA WITH A TOTAL SURVIVAL PERIOD OF MORE THAN 3 YEARS.
EHA Library, Juan Li, 421539
MANAGEMENT OF MULTIPLE MYELOMA WITH RENAL FAILURE IN ALGERIA
EHA Library, S.M.Amine BENLAZAR, 421540
DOUBLE VERSUS SINGLE AUTOLOGOUS STEM CELL TRANSPLANT IN ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD MULTICENTRE REPORT
EHA Library, Danilo De Novellis, 421541
PREDICTORS OF RENAL RESPONSE AND SURVIVAL OUTCOMES IN CAST NEPHROPATHY
EHA Library, Wai Nga Grace Lau, 421543
EVALUATION OF ELRANATAMAB VS EPD, PVD, OR KD IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR ANTI-CD38–DIRECTED THERAPY: MAGNETISMM-32
EHA Library, Satoshi Ito, 421544
AL AMYLOIDOSIS : BRIDGING GAPS IN KNOWLEDGE FOR IMPROVED PATIENT OUTCOMES : A RETROSPECTIVE REVIEW
EHA Library, amal chalbaoui, 421545
PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE WHO RESPOND TO SILTUXIMAB DEMONSTRATE SIGNIFICANT MEAN REDUCTION IN C-REACTIVE PROTEIN LEVELS COMPARED WITH SILTUXIMAB NON-RESPONDERS
EHA Library, JEANFRANCOIS ROSSI, 421546
DARATUMUMAB-BASED THERAPY IN PATIENTS WITH MULTIPLE MYELOMA AT FIRST RELAPSE/PROGRESSION: A MULTICENTER REAL-LIFE STUDY
EHA Library, Fengyan Jin, 421547
COMPREHENSIVE GERIATRIC ASSESSMENT AND CLINICAL OUTCOMES OF MULTIPLE MYELOMA PATIENTS IN A LATIN AMERICAN UNIVERSITY HOSPITAL
EHA Library, Claudia Sossa-Melo, 421548
A RETROSPECTIVE MULTICENTRE REAL-LIFE EXPERIENCE OF SAFETY OF SUBCUTANEOUS DARATUMUMAB IN PLASMA CELL DISORDERS
EHA Library, Danilo De Novellis, 421549
HETEROGENEITY AMONG FRAIL MYELOMA PATIENTS, FROM ‘FRAIL BASED ON AGE ALONE’ TO ‘ULTRA-FRAIL’, IS ASSOCIATED WITH CLINICAL OUTCOME
EHA Library, Kaz Groen, 421550
DEMOGRAPHIC AND BASELINE CHARACTERISTICS OF PATIENTS IN CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) PHASE 3 TRIALS ASSESSING SAFETY AND EFFICACY OF ANSELAMIMAB IN LIGHT CHAIN AMYLOIDOSIS
EHA Library, Ashutosh Wechalekar, 421551
CYTOMEGALOVIRUS REACTIVATION IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB AS FIRST- OR SECOND-LINE THERAPY: A SINGLE INSTITUTION RETROSPECTIVE EXPERIENCE
EHA Library, Danilo De Novellis, 421552
MULTIPLE MYELOMA: 25-YEAR RETROSPECTIVE SINGLE-CENTER STUDY (ST. PETERSBURG, RUSSIA)
EHA Library, Sergey Voloshin, 421553
MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE IN A MEDIUM SIZED DISTRICT GENERAL HOSPITAL IN THE UNITED KINGDOM
EHA Library, Zarnain Syed, 421554
SINGLE-CENTER EXPERIENCE OF THERAPEUTIC INTENSIFICATION FOLLOWED BY AUTOTRANSPLANTATION OF NON-CRYOPOIETIC STEM CELLS IN MULTIPLE MYELOMA
EHA Library, Salima OUKID, 421555
IMPACT OF DARA-VTD INDUCTION THERAPY ON STEM CELL MOBILIZATION OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION: A MULTICENTER STUDY.
EHA Library, Roberta Della Pepa, 421556
HIGH RATES OF STRINGENT COMPLETE RESPONSE AND MRD NEGATIVITY AFTER DARATUMUMAB BASED INDUCTION QUADRUPLETS IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (TE-NDMM) IN THE REAL-WORLD.
EHA Library, Grigorios Salvaras, 421557
CLINICAL OUTCOMES AND MICROBIOLOGICAL DATA IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE OBSERVATIONAL STUDY OF 92 SUBJECTS
EHA Library, Antonio Solimando, 421558
OUTCOME OF PATIENTS WITH MULTIPLE MYELOMA USING NON-CRYOPRESERVED STEM CELLS TRANSPLANT
EHA Library, Qudrat Ullah, 421559
EVALUATING MYOCARDIAL INVOLVEMENT IN PATIENTS WITH MULTIPLE MYELOMA AT DIFFERENT STAGES :A CARDIAC MR T1 MAPPING STUDY
EHA Library, Peihong Guo, 421560
THE EFFECT OF CD38 EXPRESSION ON THE BONE MARROW PLASMA CELLS AFTER DARATUMUMAB TREATMENT ON DISEASE OUTCOME IN  MULTIPLE MYELOMA PATIENTS
EHA Library, Muhammed Enes CEYLAN, 421561
ISA-KD TREATMENT: EFFICACY IN MMRR PATIENTS WITH PRE-EXISTING SOFT-TISSUE PLASMACYTOMAS. REAL WORLD EVIDENCE.
EHA Library, María Dunia De Miguel Llorente, 421562
HEAVY/LIGHT CHAIN RESPONSE CRITERIA IN MULTIPLE MYELOMA CORRELATES BETTER WITH PROGNOSIS.
EHA Library, Sunil Lakhwani, 421563
DARATUMUMAB IN MULTIPLE MYELOMA. INITIAL EXPERIENCE IN A SINGLE CENTER IN CHILE.
EHA Library, Marcela Espinoza, 421564
A RETROSPECTIVE STUDY OF TREATMENT AND OUTCOMES OF AL AMYLOIDOSIS IN THE ERA OF MODERN DIAGNOSTICS AND NOVEL THERAPEUTIC AGENTS:  A TERTIARY CARE CENTRE EXPERIENCE FROM NORTHERN INDIA
EHA Library, PRIYANKA MOULE, 421565
DEVELOPMENT AND VALIDATION OF A NOVEL FRAILTY MODEL FOR PATIENTS WITH MULTIPLE MYELOMA
EHA Library, biao tian, 421566
LONG-TERM EFFICACY OF CAR-T THERAPY IN PATIENTS WITH FIRST RELAPSE OR PROGRESSIVE MULTIPLE MYELOMA
EHA Library, Yi Wang, 421567
SELINEXOR AND MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
EHA Library, Jiali Li, 421568
ABSENCE OF PROGRESSION WITHIN THREE YEARS MAY IDENTIFY A SUBGROUP OF LONG-TERM SURVIVORS WITH MULTIPLE MYELOMA
EHA Library, Shuangshuang Jia, 421569
MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Library, Alexander Lesokhin, 421570
AL AMYLOID CARDIOMYOPATHY : UNVEILING THE CARDIAC IMPLICATIONS OF IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS
EHA Library, amal chalbaoui, 421571
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS WHOSE MYELOMA DEFINING EVENT WAS SLIM
EHA Library, Iuliana Vaxman, 421572
HEAVY/LIGHT CHAIN ANALYSIS CORRELATES WITH CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS DURING THE DISEASE HISTORY
EHA Library, Cátia Almeida, 421573
PROGNOSTIC FACTORS INFLUENCING OVERALL SURVIVAL AND EVENT-FREE SURVIVAL IN ELDERLY WITH MULTIPLE MYELOMA
EHA Library, Bizid Inaam, 421574
POTENTIAL OF SERUM B-CELL MATURATION ANTIGEN LEVELS AS A DISEASE MONITORING BIOMARKER IN OLIGOSECRETORY RELAPSED MULTIPLE MYELOMA
EHA Library, Daisuke Ikeda, 421575
ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL WORLD EVIDENCE (RWE).
EHA Library, María Dunia De Miguel Llorente, 421576
COMPARATIVE EFFICACY OF TECLISTAMAB VERSUS POMALIDOMIDE PLUS DEXAMETHASONE FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA IN ENGLAND
EHA Library, Esther Cheah, 421577
SYSTEMIC MASTOCYTOSIS CLASSIFICATION AND TRYPTASE AND ß-2-MICROGLOBULINE LEVELS HELP IDENTIFY CASES IN WHICH PURIFICATION OF MAST CELLS CAN BE AVOIDED
EHA Library, Miguel Piris Villaespesa, 421578
PLATELET MULTI-OMICS ANALYSIS CONFIRMS HYPERGLYCEMIA AS A RISK FACTOR FOR THROMBOSIS IN JAK2V617F-POSITIVE ESSENTIAL THROMBOCYTHEMIA
EHA Library, Jia Chen, 421579

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings